Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2005 by Alexion Pharmaceuticals.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Procter and Gamble
Information provided by:
Alexion Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00088179
First received: July 21, 2004
Last updated: August 28, 2005
Last verified: August 2005
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given
No publications provided by Alexion Pharmaceuticals

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):